;
Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • ReN001: Phase II start

    ReNeuron Group plc (LSE:RENE), Guildford, U.K. Product: ReN001 Business: Neurology Molecular target: Not applicable Description: Cell therapy consisting of neural stem cells derived from ReNeuron's c-mycER technology …

    Published on 4/14/2014
  • RetinoStat: Completed Phase I enrollment

    Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Product: RetinoStat Business: Ophthalmic Molecular target: NA Description: LentiVector-based gene therapy designed to deliver 2 anti-angiogenic genes, endostatin and …

    Published on 4/14/2014
  • Scyllo-inositol: Phase II discontinued

    Transition Therapeutics Inc. (TSX:TTH; NASDAQ:TTHI), Toronto, Ontario Product: Scyllo-inositol (AZD-103, ELND005) Business: Neurology Molecular target: Beta amyloid Description: Small molecule that disaggregates beta …

    Published on 4/14/2014
  • Tecemotide: Phase III started

    Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Merck KGaA (Xetra:MRK), Darmstadt, Germany Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Product: Tecemotide (L-BLP25) (formerly Stimuvax) Business: Cancer …

    Published on 4/14/2014
  • TNF-Kinoid: Completed Phase IIb enrollment

    Neovacs S.A. (Euronext:ALNEV), Paris, France Product: TNF-Kinoid (formerly TNFalpha kinoid) Business: Autoimmune Molecular target: Tumor necrosis factor (TNF) alpha Description: Immunotherapy against tumor necrosis …

    Published on 4/14/2014
  • AN2728: Phase III started

    Anacor Pharmaceuticals Inc. (NASDAQ:ANAC), Palo Alto, Calif. Product: AN2728 Business: Dermatology Molecular target: Phosphodiesterase-4 (PDE-4); Tumor necrosis factor (TNF) alpha Description: Topical borinic acid ester…

    Published on 4/7/2014
  • Belviq lorcaserin: Phase II started

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA), San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Belviq lorcaserin (APD356) Business: Neurology Molecular target: Serotonin (5-HT2C) receptor Description: …

    Published on 4/7/2014
  • Combo Dual Therapy Stent: Completed postmarketing study enrollment

    OrbusNeich, Hong Kong, China Product: Combo Dual Therapy Stent (formerly Combo Bio-engineered Sirolimus Eluting Stent) Business: Cardiovascular Molecular target: NA Description: Abluminal sirolimus-eluting stent with …

    Published on 4/7/2014
  • CUDC-427: Phase I resumed

    Curis Inc. (NASDAQ:CRIS), Lexington, Mass. Genentech Inc., South San Francisco, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: CUDC-427 (formerly GDC-0917) Business: Cancer Molecular target: Inhibitor …

    Published on 4/7/2014
  • Cynviloq: Pivotal trial started

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Samyang Corp. (KSE:000070), Seoul, South Korea Product: Cynviloq (Genexol-PM) (IG-001) Business: Cancer Molecular target: NA Description: Injectable …

    Published on 4/7/2014
  • Edoxaban: Phase III started

    Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: Edoxaban (Lixiana) (DU-176b) Business: Cardiovascular Molecular target: Factor Xa Description: Oral Factor Xa inhibitor Indication: Prevent stroke and systemic…

    Published on 4/7/2014
  • Firdapse amifampridine: Completed Phase III enrollment

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Novato, Calif. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Product: Firdapse amifampridine …

    Published on 4/7/2014
  • GT-MAB 5: Phase IIb started

    Glycotope GmbH, Berlin, Germany Product: GT-MAB 5.2-GEX (CetuGEX) Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Human version of cetuximab, a chimeric mAb against EGFR …

    Published on 4/7/2014
  • ICEF15: Phase IIb started

    Innovacell Biotechnologie AG, Innsbruck, Austria Norgine B.V., Amsterdam, the Netherlands Product: ICEF15 Business: Genitourinary Molecular target: NA Description: Cell therapy product based on proliferating autologous …

    Published on 4/7/2014
  • Lirilumab: Phase I ongoing

    Innate Pharma S.A. (Euronext:IPH), Marseille, France Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Lirilumab (BMS-986015, IPH2102) Business: Cancer Molecular target: Killer cell immunoglobulin-like …

    Published on 4/7/2014
  • MGN1703: Phase II started

    Mologen AG (Xetra:MGN), Berlin, Germany Product: MGN1703 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Toll-like receptor 9 (TLR9) agonist based on double Stem Loop Immunomodulator (dSLIM) …

    Published on 4/7/2014
  • Mifepristone: Phase I started

    Corcept Therapeutics Inc. (NASDAQ:CORT), Menlo Park, Calif. Product: Mifepristone (Corluxin, Korlym) (formerly Corlux) Business: Cancer Molecular target: Progesterone receptor; Cortisol receptor GR-2 Description: …

    Published on 4/7/2014
  • Nivolumab: Phase I ongoing

    Ono Pharmaceutical Co. Ltd. (Tokyo:4528), Osaka, Japan Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Nivolumab (ONO-4538, MDX-1106, BMS-936558) Business: Cancer Molecular target: Programmed cell death 1 (…

    Published on 4/7/2014
  • PEGPH20: Phase II halted

    Halozyme Therapeutics Inc. (NASDAQ:HALO), San Diego, Calif. Product: PEGPH20 (formerly PEGrHuPH20) Business: Cancer Molecular target: Hyaluronan Description: Recombinant human PH20 hyaluronidase enzyme conjugated to …

    Published on 4/7/2014
  • RO6895882: Phase I started

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RO6895882, RG7813 Business: Cancer Molecular target: Carcinoembryonic antigen (CEA) Description: Immunocytokine combining an engineered cytokine (IL-2v) with an …

    Published on 4/7/2014
  • SD-101: Completed Phase IIb enrollment

    Scioderm LLC, Raleigh, N.C. Product: SD-101 Business: Dermatology Molecular target: NA Description: Undisclosed topical cream Indication: Treat epidermolysis bullosa Endpoint: Target wound closure within 1 month; change…

    Published on 4/7/2014
  • Simeprevir: Phase III started

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Simeprevir (Sovriad, Galexos, Olysio) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 4/7/2014
  • Simeprevir: Phase III started

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Simeprevir (Sovriad, Galexos, Olysio) (TMC435) (formerly TMC435350) Business: Infectious Molecular target: HCV NS3/4A …

    Published on 4/7/2014
  • Sustol: Phase III started

    Heron Therapeutics Inc. (NASDAQ:HRTX), Redwood City, Calif. Product: Sustol (APF530) Business: Gastrointestinal Molecular target: Serotonin (5-HT3) receptor Description: Long-acting formulation of granisetron, a …

    Published on 4/7/2014
  • Xofigo radium-223: Phase III started

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Xofigo radium-223 (BAY88-8223) (formerly Alpharadin) Business: Cancer Molecular target: Not available Description: Radiopharmaceutical based on the alpha particle …

    Published on 4/7/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993